Skip to main content

Together we are beating cancer

Donate now

Cancer News

The latest news, analysis and opinion from Cancer Research UK

Drug decision

Showing 12 out of 19 results
broken cigarette on yellow background

Varenicline has been shown to work as well as vapes and better than nicotine patches. It could prevent 9,500 deaths in the next five years. Varenicline has been shown to work as well as vapes and better than nicotine patches. It could prevent 9,500 deaths in the next five years.

by Tim Gunn | News | 12 November 2024

12 November 2024

purple stained multiple myeloma cells

The National Institute for Health and Care Excellence (NICE) has recommended the use of elranatamab for adults with multiple myeloma, a cancer that forms in a type of white blood cell called a plasma cell. The National Institute for Health and Care Excellence (NICE) has recommended the use of elranatamab for adults with multiple myeloma, a cancer that forms in a type of white blood cell called a plasma cell.

by Sophie Wedekind | News | 1 November 2024

1 November 2024

stained microscopic sample of stomach cancer cells

The immunotherapy drug pembrolizumab (also known as Keytruda) has been approved as an option for people with advanced gastric cancer. The immunotherapy drug pembrolizumab (also known as Keytruda) has been approved as an option for people with advanced gastric cancer.

by Sophie Wedekind | News | 7 August 2024

7 August 2024

Cancer Research UK scientists in the lab

NHS England will offer the newly-approved dabrafenib plus trametinib combination to children and young people whose gliomas are being driven by a specific genetic mutation. NHS England will offer the newly-approved dabrafenib plus trametinib combination to children and young people whose gliomas are being driven by a specific genetic mutation.

by Tim Gunn | News | 13 June 2024

13 June 2024

Endometrial adenocarcinoma cells viewed under the microscope

Dostarlimab (also called Jemperli) has been recommended by the National Institute of Health and Care Excellence (NICE) to treat some types of advanced or recurrent womb cancer Dostarlimab (also called Jemperli) has been recommended by the National Institute of Health and Care Excellence (NICE) to treat some types of advanced or recurrent womb cancer

by Jacob Smith | News | 8 March 2024

8 March 2024

Two Cancer Research UK-funded researchers in their lab.

The MHRA has licensed anastrozole as a way to prevent breast cancer in almost 300,000 women. Our trial showed that it can halve their risk. The MHRA has licensed anastrozole as a way to prevent breast cancer in almost 300,000 women. Our trial showed that it can halve their risk.

by Tim Gunn | News | 7 November 2023

7 November 2023

A magnified image of squamous cell carcinoma, the most common type of cervical cancer

The immunotherapy pembrolizumab may help some people with incurable cervical cancer live longer. It's now an approved treatment for them in England and Scotland. The immunotherapy pembrolizumab may help some people with incurable cervical cancer live longer. It's now an approved treatment for them in England and Scotland.

by Tim Gunn | News | 16 May 2023

16 May 2023

Breast cancer cells

Olaparib, a targeted cancer drug discovered and developed with our funding, has been approved for hundreds of patients with certain breast and prostate cancers in England.  Olaparib, a targeted cancer drug discovered and developed with our funding, has been approved for hundreds of patients with certain breast and prostate cancers in England. 

by Tim Gunn | News | 11 April 2023

11 April 2023

Breast cancer cell seen through a scanning electron microscope

The "potentially life-saving" immunotherapy drug pembrolizumab is now recommended for some people with early triple negative breast cancer in England and Wales. The "potentially life-saving" immunotherapy drug pembrolizumab is now recommended for some people with early triple negative breast cancer in England and Wales.

by Tim Gunn | News | 14 November 2022

14 November 2022